Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 10, Pages 5115
Publisher
MDPI AG
Online
2021-05-12
DOI
10.3390/ijms22105115
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exploiting allosteric properties of RAF and MEK inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling
- (2021) Christos Adamopoulos et al. Cancer Discovery
- Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review
- (2021) Luca Tagliaferri et al. Human Vaccines & Immunotherapeutics
- DNA hypermethylation associated with upregulated gene expression in prostate cancer demonstrates the diversity of epigenetic regulation
- (2020) Ieva Rauluseviciute et al. BMC Medical Genomics
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
- (2020) Paolo A. Ascierto et al. EUROPEAN JOURNAL OF CANCER
- Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
- (2020) Shannon Lee et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy
- (2020) Magdalena Olbryt et al. Targeted Oncology
- A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma
- (2020) Yangzi Tian et al. MEDICAL SCIENCE MONITOR
- RASSF1A Tumour Suppressor: Target the Network for Effective Cancer Therapy
- (2020) Lucía García-Gutiérrez et al. Cancers
- Targeted Therapy in Melanoma and Mechanisms of Resistance
- (2020) Anna M. Czarnecka et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Current State of Target Treatment in BRAF Mutated Melanoma
- (2020) Enrica Teresa Tanda et al. Frontiers in Molecular Biosciences
- Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
- (2020) Ilaria Proietti et al. Cancers
- Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies
- (2020) Ozgecan Dulgar et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review
- (2020) Lokeswari P. Tangella et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
- (2020) Paola Savoia et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy
- (2020) Mirna Swayden et al. Cells
- MITF has a central role in regulating starvation-induced autophagy in melanoma
- (2019) Katrin Möller et al. Scientific Reports
- NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells
- (2019) Maureen Keller et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance
- (2019) Daniël A. Lionarons et al. CANCER CELL
- DNA hypermethylation in disease: mechanisms and clinical relevance
- (2019) Melanie Ehrlich Epigenetics
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Methylation Dynamics of RASSF1A and Its Impact on Cancer
- (2019) Giorgio Malpeli et al. Cancers
- Current state of melanoma diagnosis and treatment
- (2019) Lauren E. Davis et al. CANCER BIOLOGY & THERAPY
- Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
- (2019) Alessandro Rossi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis—an updated review
- (2019) Fatéméh Dubois et al. Cell Death & Disease
- Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
- (2018) Markus Hecht et al. BRITISH JOURNAL OF CANCER
- Melanoma: What do all the mutations mean?
- (2018) Elizabeth J. Davis et al. CANCER
- RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis
- (2018) M. Lee Schmidt et al. CANCER RESEARCH
- Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic
- (2018) Khushboo Agrawal et al. PHARMACOLOGY & THERAPEUTICS
- ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
- (2018) Shujun Han et al. Nature Communications
- Upregulation of RASSF1A in Colon Cancer by Suppression of Angiogenesis Signaling and Akt Activation
- (2018) Thomas G. Blanchard et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- RASSF1A suppresses colorectal tumor cell growth through p53-dependent p21WAF1 activation
- (2018) Shin Ju Oh et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- YAPping about and not forgetting TAZ
- (2018) Bernard A. Callus et al. FEBS LETTERS
- Promoter methylation as biomarkers for diagnosis of melanoma: A systematic review and meta-analysis
- (2018) Yu Guo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Impact of Natural Compounds on DNA Methylation Levels of the Tumor Suppressor Gene RASSF1A in Cancer
- (2017) Reinhard Dammann et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
- (2017) Ursula A. Germann et al. MOLECULAR CANCER THERAPEUTICS
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition
- (2017) P Dietrich et al. ONCOGENE
- Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells
- (2017) Matthew L. Fisher et al. Oncotarget
- The tumor suppressor RASSF1A induces the YAP1 target gene ANKRD1 that is epigenetically inactivated in human cancers and inhibits tumor growth
- (2017) Adriana P. Jiménez et al. Oncotarget
- Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study
- (2017) Yousef Zakharia et al. Oncotarget
- The loss-of-function of DNA methyltransferase 1 by siRNA impairs the growth of non-small cell lung cancer with alleviated side effects via reactivation of RASSF1A and APC in vitro and vivo
- (2017) Qi Lai et al. Oncotarget
- Diagnostic Capacity of RASSF1A Promoter Methylation as a Biomarker in Tissue, Brushing, and Blood Samples of Nasopharyngeal Carcinoma
- (2017) Meng Ye et al. EBioMedicine
- RASSF1A Directly Antagonizes RhoA Activity through the Assembly of a Smurf1-Mediated Destruction Complex to Suppress Tumorigenesis
- (2016) Min-Goo Lee et al. CANCER RESEARCH
- RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway
- (2016) Fatéméh Dubois et al. CANCER RESEARCH
- Mechanisms of Hippo pathway regulation
- (2016) Zhipeng Meng et al. GENES & DEVELOPMENT
- Targeting the Hippo signalling pathway for cancer treatment
- (2016) Keisuke Nakatani et al. JOURNAL OF BIOCHEMISTRY
- Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
- (2016) Gao Zhang et al. JOURNAL OF CLINICAL INVESTIGATION
- Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma
- (2016) Minggang Fang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- (2016) I. Tirosh et al. SCIENCE
- BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy
- (2016) Mudit Chowdhary et al. OncoTargets and Therapy
- Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
- (2016) M. A. Miller et al. Cancer Discovery
- Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine
- (2016) Costantine Albany et al. Oncotarget
- Metastatic Melanoma – A Review of Current and Future Treatment Options
- (2015) E Maverakis et al. ACTA DERMATO-VENEREOLOGICA
- Clinical utility of RASSF1A methylation in human malignancies
- (2015) A M Grawenda et al. BRITISH JOURNAL OF CANCER
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Safeguarding genome stability: RASSF1A tumor suppressor regulates BRCA2 at stalled forks
- (2015) Dafni Eleftheria Pefani et al. CELL CYCLE
- RAC1 and Melanoma
- (2015) Ruth Halaban CLINICAL THERAPEUTICS
- Epigenetic regulation in human melanoma: past and future
- (2015) Debina Sarkar et al. Epigenetics
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
- (2015) Jinhua Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors
- (2015) Rohit Arora et al. JOURNAL OF MEDICINAL CHEMISTRY
- Adjusting for the Confounding Effects of Treatment Switching--The BREAK-3 Trial: Dabrafenib Versus Dacarbazine
- (2015) N. R. Latimer et al. ONCOLOGIST
- Broad targeting of resistance to apoptosis in cancer
- (2015) Ramzi M. Mohammad et al. SEMINARS IN CANCER BIOLOGY
- BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
- (2015) Francesco Spagnolo et al. OncoTargets and Therapy
- PDGFRα up-regulation mediated by Sonic Hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation
- (2015) Francesco Sabbatino et al. Oncotarget
- Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
- (2014) Moriah H. Nissan et al. CANCER RESEARCH
- The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
- (2014) Ian R. Watson et al. CANCER RESEARCH
- MITF in melanoma: mechanisms behind its expression and activity
- (2014) Mariusz L. Hartman et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
- (2014) H. Rizos et al. CLINICAL CANCER RESEARCH
- The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
- (2014) F. Fang et al. CLINICAL CANCER RESEARCH
- Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
- (2014) M. S. Carlino et al. CLINICAL CANCER RESEARCH
- Cell Cycle Restriction Is More Important Than Apoptosis Induction for RASSF1A Protein Tumor Suppression
- (2014) Howard Donninger et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
- (2014) Georgina V. Long et al. Nature Communications
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- (2014) D. J. Konieczkowski et al. Cancer Discovery
- Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
- (2013) E. Romano et al. CLINICAL CANCER RESEARCH
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
- (2013) K. L. Nathanson et al. CLINICAL CANCER RESEARCH
- Historical review of melanoma treatment and outcomes
- (2013) Carrie Lee et al. CLINICS IN DERMATOLOGY
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- The Differential Effects of Wild-Type and Mutated K-Ras on MST2 Signaling Are Determined by K-Ras Activation Kinetics
- (2013) David Romano et al. MOLECULAR AND CELLULAR BIOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
- (2013) Alastair J. King et al. PLoS One
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
- (2013) Jessie Villanueva et al. Cell Reports
- A Landscape of Driver Mutations in Melanoma
- (2012) Eran Hodis et al. CELL
- A brief history of melanoma
- (2012) Vito W. Rebecca et al. MELANOMA RESEARCH
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
- (2012) Michael Krauthammer et al. NATURE GENETICS
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- The Tumor Suppressor RASSF1A Prevents Dephosphorylation of the Mammalian STE20-like Kinases MST1 and MST2
- (2011) Cai Guo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutant K-Ras Activation of the Proapoptotic MST2 Pathway Is Antagonized by Wild-Type K-Ras
- (2011) David Matallanas et al. MOLECULAR CELL
- Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care
- (2011) Richard A. Scolyer et al. Molecular Oncology
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Regulation of APC/CCdc20 activity by RASSF1A–APC/CCdc20 circuitry
- (2011) C Chow et al. ONCOGENE
- Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells
- (2011) Y Cheli et al. ONCOGENE
- Cross-Regulation between Oncogenic BRAFV600E Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma
- (2011) Seong Jin Lee et al. PLoS One
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Proapoptotic Kinase MST2 Coordinates Signaling Crosstalk between RASSF1A, Raf-1, and Akt
- (2010) D. Romano et al. CANCER RESEARCH
- Defining the patient at high risk for melanoma
- (2010) Estee L. Psaty et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- RASSF1A suppresses melanoma development by modulating apoptosis and cell-cycle progression
- (2010) Mei Yi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Decoding Melanoma Metastasis
- (2010) William E. Damsky et al. Cancers
- Aberrant CpG Island Hypermethylation of RASSF1A in Gastric Cardia Adenocarcinoma
- (2009) Wei Guo et al. CANCER INVESTIGATION
- Aurora A Regulates Prometaphase Progression by Inhibiting the Ability of RASSF1A to Suppress APC-Cdc20 Activity
- (2009) S. J. Song et al. CANCER RESEARCH
- RASSF1A Mediates p21Cip1/Waf1-Dependent Cell Cycle Arrest and Senescence through Modulation of the Raf-MEK-ERK Pathway and Inhibition of Akt
- (2009) S. Thaler et al. CANCER RESEARCH
- Loss of RhoB Expression Promotes Migration and Invasion of Human Bronchial Cells Via Activation of AKT1
- (2009) E. Bousquet et al. CANCER RESEARCH
- ATM Regulates a RASSF1A-Dependent DNA Damage Response
- (2009) Garth Hamilton et al. CURRENT BIOLOGY
- Molecular Markers of Tumor Progression in Melanoma
- (2009) Joshua Rother et al. CURRENT GENOMICS
- Melanoma Epidemiology
- (2009) Margaret A. Tucker HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation
- (2009) Y Aylon et al. ONCOGENE
- Fifteen-year quest for microphthalmia-associated transcription factor target genes
- (2009) Yann Cheli et al. Pigment Cell & Melanoma Research
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
- The “dysplastic” nevus
- (2008) Robert J. Friedman et al. CLINICS IN DERMATOLOGY
- The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2–DAXX–HAUSP complex
- (2008) Min Sup Song et al. EMBO JOURNAL
- The RASSF1A Tumor Suppressor Restrains Anaphase-Promoting Complex/Cyclosome Activity during the G1/S Phase Transition To Promote Cell Cycle Progression in Human Epithelial Cells
- (2008) A. W. Whitehurst et al. MOLECULAR AND CELLULAR BIOLOGY
- Dynamics of RASSF1A/MOAP-1 Association with Death Receptors
- (2008) C. J. Foley et al. MOLECULAR AND CELLULAR BIOLOGY
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started